Plans encouraged by activities that lift obesity's heavy burnden

March 1, 2004

Article

Overweight members tally up disproportionate medical costs, but DM programs prove to be effective in lifestyle makeovers

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Related Content

FDA Committee Recommends Sanofi/AstraZeneca’s RSV Vaccine for Infants

Christine Blank

June 12th 2023

Article

If approved, nirsevimab would be the first immunization specifically to protect infants through their first RSV season. The Prescription Drug User Fee Act date is in the third quarter of 2023.

FDA Approves First Pediatric Indication for Blockbuster Eylea

Christine Blank

February 9th 2023

Article

Eylea now also treats retinopathy of prematurity, a leading cause of childhood blindness worldwide.

FDA Accepts BLA for RSV Prevention in Infants

January 5th 2023

Article

Nirsevimab is a single-dose, long-acting antibody to protect infants from respiratory syncytial virus (RSV) lower respiratory tract infections. The FDA action date is in the third quarter of 2023.

Wegovy Approved for Teens; Supply May be Delayed

Christine Blank

January 4th 2023

Article

Wegovy is a once-weekly prescription medication for obesity that has faced supply issues. Its manufacturer, Novo Nordisk, is increasing production capacity in 2023.

AbbVie Submits sNDA for Linzess for Children and Adolescents

December 17th 2022

Article

If approved, Linzess would be the first prescription therapy for functional constipation in children and adolescents 6 to 17 years of age.

FDA Grants Six Months Pediatric Exclusivity for Eylea

October 21st 2022

Article

Eylea is being reviewed as a treatment for retinopathy in premature infants.

Related Content

FDA Committee Recommends Sanofi/AstraZeneca’s RSV Vaccine for Infants

Christine Blank

June 12th 2023

Article

If approved, nirsevimab would be the first immunization specifically to protect infants through their first RSV season. The Prescription Drug User Fee Act date is in the third quarter of 2023.

FDA Approves First Pediatric Indication for Blockbuster Eylea

Christine Blank

February 9th 2023

Article

Eylea now also treats retinopathy of prematurity, a leading cause of childhood blindness worldwide.

FDA Accepts BLA for RSV Prevention in Infants

January 5th 2023

Article

Nirsevimab is a single-dose, long-acting antibody to protect infants from respiratory syncytial virus (RSV) lower respiratory tract infections. The FDA action date is in the third quarter of 2023.

Wegovy Approved for Teens; Supply May be Delayed

Christine Blank

January 4th 2023

Article

Wegovy is a once-weekly prescription medication for obesity that has faced supply issues. Its manufacturer, Novo Nordisk, is increasing production capacity in 2023.

AbbVie Submits sNDA for Linzess for Children and Adolescents

December 17th 2022

Article

If approved, Linzess would be the first prescription therapy for functional constipation in children and adolescents 6 to 17 years of age.

FDA Grants Six Months Pediatric Exclusivity for Eylea

October 21st 2022

Article

Eylea is being reviewed as a treatment for retinopathy in premature infants.